세계의 남성형 탈모 치료제 시장 : 치료 유형별, 성별, 약물 유형별, 최종 용도별 - 예측(2024-2032년)

Global Androgenetic Alopecia Treatment Market will witness 7.6% CAGR between 2024 and 2032, driven by advancements in clinical trials and research and development in the field. AGA, commonly known as male or female pattern baldness, affects millions worldwide, creating a substantial market for effective treatments. Recent years have seen groundbreaking research leading to novel therapeutic approaches. For instance, in January 2024, HopeMed advanced its androgenetic alopecia treatment to Phase II trials. The China-based pharmaceutical company initiated Phase II recruitment following the positive outcomes of its prolactin receptor antibody in a Phase I study. The hospital commenced recruitment for a Phase II trial to evaluate its monoclonal antibody HMI-115 for androgenetic alopecia recently.

Advanced clinical trials are exploring innovative solutions, including gene therapy, stem cell treatments, and novel pharmacological agents that target the underlying mechanisms of hair loss. The growing understanding of genetic and molecular pathways involved in AGA has paved the way for targeted therapies, offering hope for more effective and personalized treatments. Furthermore, advancements in biotechnology and medical technology are enhancing the precision and efficacy of these treatments. As research continues to progress, the promise of more efficient, safe, and long-lasting solutions for AGA is driving increased demand and investment in this dynamic field.

The overall androgenetic alopecia treatment Industry size is classified based on the treatment type, gender, medication type, end-use, and region.

The device segment will undergo rigorous development from 2024 to 2032. Devices such as low-level laser therapy (LLLT) caps, microneedling rollers, and scalp cooling systems have gained popularity due to their non-invasive nature and ease of use. These devices offer a convenient alternative to traditional pharmacological treatments, attracting individuals seeking effective and user-friendly solutions. Additionally, the continuous innovation in device technology enhances treatment efficacy, making them an appealing option for both men and women experiencing hair loss. As a result, the market for AGA treatment devices is expanding, meeting the growing demand for effective hair restoration methods.

The androgenetic alopecia treatment market revenue from the female segment will register a notable CAGR from 2024 to 2032. Traditionally considered a male issue, AGA affects a substantial number of women, causing distress and impacting self-esteem. As more women seek effective solutions, the market has responded with treatments tailored to female needs, including topical solutions, oral medications, and advanced therapies like platelet-rich plasma (PRP) and low-level laser therapy (LLLT). Additionally, the growth of research specifically focused on female hair loss has led to more effective and targeted treatments, further fueling demand. This shift reflects a growing recognition of the importance of addressing AGA in women.

Europe androgenetic alopecia treatment market will showcase a commendable CAGR from 2024 to 2032. European consumers are becoming more proactive about addressing hair loss, leading to higher adoption rates of both traditional and innovative treatments. This includes topical minoxidil, oral finasteride, and newer options like platelet-rich plasma (PRP) therapy and low-level laser therapy (LLLT). The European market's emphasis on cutting-edge research and development has led to more effective, personalized treatment options. Additionally, societal shifts towards prioritizing appearance and well-being are contributing to the growing demand for AGA treatments across the continent.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of androgenetic alopecia
    • 3.2.1.2 Technological advancements in treatment
    • 3.2.1.3 Growing awareness about alopecia treatment options
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Start-up scenario
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmaceutical
  • 5.2.1 Topical
  • 5.2.2 Oral
• 5.3 Device
  • 5.3.1 Laser cap
  • 5.3.2 Laser comb
  • 5.3.3 Laser helmet
• 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription
• 7.3 OTC

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Dermatology clinics
• 8.3 Homecare settings
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Apira Science, Inc. (iGROW Laser)
• 10.2 Aurobindo Pharma
• 10.3 Cipla, Inc.
• 10.4 Curallux, LLC
• 10.5 Dr. Reddy's Laboratories Ltd.
• 10.6 Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
• 10.7 Johnson & Johnson Services, Inc.
• 10.8 Lexington Intl., LLC
• 10.9 Merck & Co., Inc.
• 10.10 Theradome Inc.